EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieStudienprotokollOpen Access · CC BY-NC 4.0

The CHRONO trial: Protocol for a randomized controlled trial of early time-restricted eating in patients with breast or rectal cancer

Sarah-Jeanne Salvy, Jane C Figueiredo, Katelyn M Atkins, Robert H Hollis, Nusrat Jahan, Drew J Gunnells, Alix G Sleight, Gillian Gresham, Márcio A Diniz, Joshua S Richman, Jun Gong, Karen Zaghiyan und 4 weitere

Nutrition Research · 2026-07 · 151 · 77-94

DOI: 10.1016/j.nutres.2026.04.016 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Nutrition Research, 2026-07. Verfasst von Sarah-Jeanne Salvy und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Samuel Oschin Comprehensive Cancer Center Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA. Electronic address: s…. Hauptthemen laut MEDLINE: Intermittent Fasting, Rectal Neoplasms, Breast Neoplasms, Fasting. Die Arbeit nennt 161 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NCI NIH HHS, National Institutes of Health National Cancer Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Fasting combined with anti-cancer therapies improves tumor regression and survival in animals. Fasting sensitizes cancer cells to cytotoxic therapies while promoting stress resistance in healthy cells, a phenomenon known as differential stress resistance. Since prolonged water-only fasting is challenging, intermittent fasting has emerged as an attractive alternative. Here, we describe the protocol of a single-blind, randomized controlled trial testing whether time-restricted eating (TRE) can improve clinical, molecular, and behavioral outcomes in cancer patients. We will enroll 175 adults with newly diagnosed stage I-III human epidermal growth factor receptor 2-positive or triple-negative breast cancer or stage II-IV rectal cancer who are receiving neoadjuvant therapy. Patients will be randomized to early TRE (eTRE; ≤8-hour eating window early in the day) or to eat over a ≥12-hour window (control group) from around the start of treatment until surgery (typically 4-8 months). The primary outcomes are the pathologic complete response, the organ preservation rate, and patient-reported adverse events. Secondary outcomes include clinical response, tumor response, quality of life, and provider-reported adverse events. To test the differential stress resistance theory, we will measure the expression of proteins involved in cell growth, cell death, and stress resistance in tumor and adjacent normal tissue. Finally, we will determine the effects of eTRE on emotional, psychosocial, and lifestyle factors and how these factors influence adherence and clinical responsiveness. This trial will provide critical insight into whether intermittent fasting can potentially improve cancer outcomes, reduce toxicities from anti-cancer therapies, and enhance quality of life in cancer patients. The study is registered on ClinicalTrials.gov (NCT04722341).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Intermittent FastingRectal NeoplasmsBreast NeoplasmsFastingHumansFemaleSingle-Blind MethodQuality of LifeAdultRandomized Controlled Trials as TopicMiddle AgedNeoadjuvant Therapy

Stichwörter der Autor:innen

Breast cancerChrononutritionDifferential stress resistanceDifferential stress sensitization theoryEarly time-restricted eatingIntermittent fastingNeoadjuvant therapyRectal cancerTime-restricted eating

Autor:innen und Institutionen

  • Department of Medicine, Samuel Oschin Comprehensive Cancer Center Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA. Electronic address: sarah.salvy@cshs.org.
  • Department of Medicine, Samuel Oschin Comprehensive Cancer Center Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
  • Department of Radiation Oncology, Samuel Oschin Comprehensive Cancer Center Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
  • Division of Gastrointestinal Surgery, O'Neal Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, AL, USA.
  • Division of Hematology and Oncology, O'Neal Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, AL, USA.
  • Chan Division of Occupational Science and Occupational Therapy, University of Southern California, Los Angeles, CA, USA.

Förderung

  • NCI NIH HHS
  • National Institutes of Health National Cancer Institute

Zitieren

APA

Salvy, S. J., Figueiredo, J. C., Atkins, K. M., Hollis, R. H., Jahan, N., Gunnells, D. J., Sleight, A. G., Gresham, G., Diniz, M. A., Richman, J. S., Gong, J., Zaghiyan, K., Heslin, M. J., Lee, K. J., Sarfraz, H., & Peterson, C. M. (2026). The CHRONO trial: Protocol for a randomized controlled trial of early time-restricted eating in patients with breast or rectal cancer. Nutrition Research, 151, 77-94. https://doi.org/10.1016/j.nutres.2026.04.016

Vancouver

Salvy SJ, Figueiredo JC, Atkins KM, Hollis RH, Jahan N, Gunnells DJ, et al. The CHRONO trial: Protocol for a randomized controlled trial of early time-restricted eating in patients with breast or rectal cancer. Nutrition Research. 2026;151:77-94. doi:10.1016/j.nutres.2026.04.016

BibTeX
@article{Salvy2026,
  author = {Salvy, Sarah-Jeanne and Figueiredo, Jane C and Atkins, Katelyn M and Hollis, Robert H and Jahan, Nusrat and Gunnells, Drew J and Sleight, Alix G and Gresham, Gillian and Diniz, Márcio A and Richman, Joshua S and Gong, Jun and Zaghiyan, Karen and Heslin, Martin J and Lee, Kevin J and Sarfraz, Humaira and Peterson, Courtney M},
  title = {The CHRONO trial: Protocol for a randomized controlled trial of early time-restricted eating in patients with breast or rectal cancer},
  journal = {Nutrition Research},
  year = {2026},
  volume = {151},
  pages = {77--94},
  doi = {10.1016/j.nutres.2026.04.016}
}
Kostenlos starten →